DDInter825 DDInter1371
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure and long-term microvascular and macrovascular complications that lead to co-morbidities and mortalities. Sulfonylureas are one of the insulin secretagogues widely used for the management of type 2 diabetes to lower blood glucose levels. The main effect of SUs is thought to be effective when residual pancreatic β-cells are present, as they work by stimulating the release of insulin from the pancreatic beta cells and they are also thought to exert extra-pancreatic effects, such as increasing the insulin-mediated peripheral glucose uptake. Glimepiride works by stimulating the secretion of insulin granules from
Oxymetholone is a synthetic anabolic steroid marketed under the brand name Anapolon by Hoffmann La Roche Limitedand used in the treatment of osteoporosis, anaemia, and as an agent to stimulate muscle growth in malnourished or underdeveloped patients. Anabolic-androgenic steroids (AAS), such as oxymetholone, have been abused by bodybuilders and athletes. The uncontrolled misuse of oxymetholone can lead to a large variety of detrimental effects, the most often reported of which are cardiovascular events. In 2009, no producers of oxymetholone were identified worldwide (SRI 2009), but it was available from 14 suppliers, including 8 U.S. suppliers (ChemSources 2009).
Glimepiride {u} (Compound) resembles {v} (Compound) Gliclazide
Glimepiride {u} (Compound) resembles {v} (Compound) Glisoxepide
Glimepiride {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
Glimepiride {u} (Compound) binds {v} (Gene) KCNJ11
Glimepiride {u} (Compound) is included by {v} (Pharmacologic Class) Sulfonylurea Compounds
Glimepiride {u} (Compound) causes {v} (Side Effect) Inappropriate antidiuretic hormone secretion
Glimepiride {u} may cause a minor interaction that can limit clinical effects when taken with {v} Methylcellulose
Glimepiride {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lipoic acid
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chromium picolinate
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sermorelin
Glimepiride (Compound) resembles Gliclazide (Compound)
Glimepiride (Compound) resembles Glisoxepide (Compound)
Glimepiride (Compound) treats type 2 diabetes mellitus (Disease)
Glimepiride (Compound) binds KCNJ11 (Gene)
Glimepiride (Compound) is included by Sulfonylurea Compounds (Pharmacologic Class)
Glimepiride (Compound) causes Inappropriate antidiuretic hormone secretion (Side Effect)
Glimepiride may cause a minor interaction that can limit clinical effects when taken with Methylcellulose
Glimepiride may cause a minor interaction that can limit clinical effects when taken with Lipoic acid
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Sermorelin